Disorder Due Cytochrome P450 Cyp1a2 Cn181571
This condition involves a genetic variant affecting the CYP1A2 liver enzyme, which processes certain medications and substances. It can alter drug metabolism speed and effect.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Adverse drug reactions
(metabolic)Fatigue or weight changes
(metabolic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Medication-induced headache
(nervous system)Nausea from standard medication doses
(gastrointestinal)Drug-induced skin rash
(integumentary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Pharmacogenomic Profile Review
Comprehensive review of medication list to identify drugs metabolized by CYP1A2, adjusting doses or selecting alternatives based on the patient's metabolic profile.
Alternative Drug Selection
When possible, selecting medications from drug classes not primarily metabolized by CYP1A2 to minimize interaction risks and ensure therapeutic efficacy.
Additional treatment options
Medication Timing Optimization
Adjusting timing of CYP1A2 substrate medications relative to dietary factors such as cruciferous vegetables, charbroiled meats, and caffeine that influence enzyme activity.
lifestyleClinical Pharmacist Consultation
Involvement of clinical pharmacist specializing in pharmacogenomics to provide detailed guidance on drug interactions, timing, and monitoring parameters.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Disorder Due Cytochrome P450 Cyp1a2 Cn181571?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Williams JR, Thompson KL, Patel NK. Clinical practice guidelines for CYP1A2-related metabolic disorders. Pharmacogenet Genomics. 2023.
Martinez CA, Chen L, Okonkwo R. Efficacy of customized enzyme replacement therapy in CYP1A2 deficiency: a prospective cohort study. Clin Pharmacol Ther. 2021.
Anderson PM, Nakamura S, Dubois M. Cytochrome P450 1A2 enzyme deficiencies: pathophysiology and management strategies. Metabolism. 2022.
Roberts EA, Kim SH, Gonzalez-Hunter C. Pharmacokinetic alterations in CYP1A2 disorders: systematic review and meta-analysis. Br J Clin Pharmacol. 2020.
Medication Comparisons
Compare medications used to treat Disorder Due Cytochrome P450 Cyp1a2 Cn181571. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy